PharmaTher Holdings Ltd (TSE:PHRM) has released an update.
PharmaTher Holdings Ltd. reported receiving a Complete Response Letter for their ANDA of Ketamine from the FDA, with no new deficiencies found. The company is set to address the FDA’s feedback and resubmit for a revised goal date, staying optimistic about eventual FDA approval to alleviate the U.S. ketamine shortage. PharmaTher is also exploring ketamine’s potential in treating pain, mental health, and neurological disorders globally.
For further insights into TSE:PHRM stock, check out TipRanks’ Stock Analysis page.
